Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar Pharma) submitted its monthly return to HKEX on 08 April 2026, detailing the completion of full share circulation during March 2026.

The company converted 147.87 million unlisted ordinary shares into H shares on 30 March, increasing registered share capital by 68.24% to RMB 364.59 million. Par value remained unchanged at RMB 1 per share.

Total issued H shares rose from 216.72 million to 364.59 million, while the unlisted share balance fell to zero. No treasury shares were created or cancelled in the process.

Biostar Pharma confirmed that the enlarged H-share class meets the Main Board’s 25% minimum public-float requirement.

The filing shows no outstanding share options, warrants, convertibles, or other equity-linked instruments for the period.